Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Endo/Women's Health TPX > Endo/Women's Health All > Flashcards

Endo/Women's Health All Flashcards

1
Q

ADA standards of DM care in 2021
A1c
Pre-prandial glucose
Peak post-prandial glucose

A

A1c < 7%
Preprandial glucose 80-130mg/dL
Peak post prandial is <180mg/dL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Metformin Efficacy

A

High

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Metformin Hypoglycemia

A

No

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Metformin Weight Loss

A

Neutral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Metformin CV Effects

A

ASCVD potential benefit

CHF neutral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Metformin Cost

A

Low

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Metformin PO/SQ

A

PO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Metformin CKD effects

A

Neutral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Metformin renal dosing

A

contra in eGFR <30

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Metformin pearls

A

GI ADE common

VB12 deficiency common

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

SGLT2i Rx names

A

Canagliflozin
Empagliflozin
Ertugliflozin
Dapagliflozin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

SGLT2i Efficacy

A

Intermediate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

SGLT2i Hypoglycemia

A

No

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

SGLT2i Weight Loss

A

Yes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

SGLT2i CV effects

A

ASCVD benefit: canagliflozin and empagliflozin

CHF benefit: canagliflozin, empagliflozin, dapagliflozin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

SGLT2i Cost

A

High

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

SGLT2i PO/SQ

A

PO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

SGLT2i CKD effects

A

benefits: canagliflozin, empagliflozin, dapagliflozin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

SGLT2i dosing

A

Canagliflozin - contra eGFR < 45
Empagliflozin - contra eGFR <30
Ertugliflozin - contra eGFR < 30
Dapagliflozin - contra eGFR <30

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

SGLT2i pearls

A 
D/C rx before any surgery to avoid DKA
DKA risk is rare in T2DM
risk of bone fractures with canagliflozin
genitourinary infections
rick of vol depletion
increase in LDL
risk of Fournier's gangrene
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

GLP1 RAs Rx

A 
Exenatide
Liraglutide
Lixisenatide
Semaglutide SQ
Semaglutide PO
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

GLP1 RAs Efficacy

A

High

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

GLP1 hypo

A

No

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

GLP1 Weight Loss

A

Yes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

GLP1 CV effects

A

ASCVD benefit - Dulaglutide, Liraglutide, Semaglutide

CHF neutral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

GLP1 costs

A

high

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

GLP1 SQ/PO

28
Q

GLP1 CKD effects

A

benefits on renal nd points in CVOTs, driven by albuminuria outcomes: liraglutide, semaglutide, dulaglutide

29
Q

GLP1 Renal dosing

A

Exenatide and lixisenatide - avoid in eGFR <30

no dosing adjustment in dulaglutide, liraglutide, or semaglutide

30
Q

GLP1 Pearls

A

BBW – risk of Thyroid C-cell tumors (all except lixisenatide)
GI ADE common
Inj site reactions
may have acute pancreatitis risk

31
Q

DPP4i Efficacy

A

intermediate

32
Q

DPP4i hypo

33
Q

DPP4 weight loss

34
Q

DPP4 CVD effects

A

ASCVD neutral

CHF potential risk: saxagliptin

35
Q

DPP4 costs

36
Q

DPP4 SQ/PO

37
Q

DPP4 CKD effects

38
Q

DPP4 renal dosing

A

Adjustment all required except for linagliptin

39
Q

DPP4 pearls

A

Risk of acute pancreatitis

Joint pain

40
Q

Thiazolidindiones (TZD) efficacy

41
Q

TZD hypo

42
Q

TZD weight loss

A

No, weight gain instead

43
Q

TZD CV effects

A

ASCVD potential benefit - pioglitazone

CHF increased risk

44
Q

TZD costs

45
Q

TZD PO/SQ

46
Q

TZD CKD effects

47
Q

TZD renal dosing

A

Not required, risk of fluid retention with renal impairment

48
Q

TZD Pearls

A

FDA BBW - CHF risk
Edema (fluid retention)
Risk of bone fractures
Risk of bladder CA (pio)

49
Q

Sulfonylureas (SU) efficacy

50
Q

SU hypo?

51
Q

SU weight loss

A

No, weight gain

52
Q

SU CV effects

A

ASCVD and CHF are neutral

53
Q

SU costs

54
Q

SU PO/SQ

55
Q

SU CKD effects

56
Q

SU renal dosing

A

Glyburide - DO.NOT.USE

Glipizide and glimepiride - start low and slow to avoid hypo

57
Q

insulin 2 forms

A

Human and analog

58
Q

Insulin efficacy

59
Q

Insulin hypo

60
Q

Insulin weight loss

61
Q

Insulin cv effects

A

ASCVD and CHF effects - neutral

62
Q

Insulin costs

63
Q

Insulin PO/SQ

64
Q

Insulin CKD effects

65
Q

Insulin Renal dosing

A

Lower insulin doses with renal impairment

Titration based on clinical reponse

66
Q

Insulin pearls

A

Injection site reactions

Hypo risk is less with analogs

Endo/Women's Health TPX (1 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions